My response is to wait until the Q2 report comes out and then get serious about the following:
If still no FDA approval, why is it taking so long since the ANDA action time (according to FDA site) is 90% in 10 months. This should be a warning sign for everyone that something is wrong.
Next, if they still haven't found any country to seek guidance or initiate the approval process, that would certainly raise a red flag in my mind. When I had contacted them, they knew about the Brexit and had mentioned another country as a possibility. This I believe was either 1 or 2 months ago.
Anyhow, I'm willing to wait until Q2 report comes out but will be very critical of the company and their management if the above hasn't been answered to my satisfaction. Especially if the guidance of $15M is also unattainable by then. I certainly wouldn't consider any sympathetic post or excuse posted a valid response to none of the above actions happening.
Agree or disagree on the above, a line must be drawn. Let's also see if they have more stock offerings and continued dilution.
